Immunic (STU:10VA) YoY EBITDA Growth : 61.17% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Immunic YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Immunic's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 61.17%.

Immunic's EBITDA per Share for the three months ended in Mar. 2024 was €-0.23.

Immunic YoY EBITDA Growth Historical Data

The historical data trend for Immunic's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunic YoY EBITDA Growth Chart

Immunic Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

87.04

40.42

-33.45

25.15

20.04

Immunic Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															15.77	19.41	25.45	20.00	61.17

Immunic YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Immunic's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-2.051	-	-2.565)	/	\| -2.565 \|
=	20.04 %

Immunic's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(-0.226	-	-0.582)	/	\| -0.582 \|
=	61.17 %

Immunic YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Immunic's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunic (STU:10VA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (STU:10VA) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

IMUX:USA 10VA:Germany

Address

1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036

Website

https://www.imux.com

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Immunic (STU:10VA) Headlines

No Headlines